A phase II study of S-1,cisplatin and lentinan in first-line treatment of unresectable or recurrent gastric cancer
- Conditions
- unresectable or recurrent gastric cancer
- Registration Number
- JPRN-UMIN000001913
- Lead Sponsor
- Yamagata University Faculty of Medicine Department of Gastroenterological, General, Breast and Thyroid Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 45
Not provided
1)Patients who have a contraindication of S-1 or cisplatin 2)Patients who had infection or inflammatory disease 3)Patients who have or had severe heart disease 4)Patients who have severe commplication, such as ileus,intestinal pneumonia,fibroid lung, uncontrolled diabetes mellitus,renal failure, liver cirrhosis and so on 5)massive asites 6)multiple bone metastases 7)brain metastases 8)fresh gastrointestinal bleeding 9)diarrhea 10)mental disorder 11)synchronous multicancer 12)Patients pregnant or in lactation, or wish to become pregnant during this study. Male patients who intend to make someone pregnant during this study 13)Men who want a baby 14)Patient who is judged to be inappropriate for this study by the principal investigator or the doctors in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method